HOME >> MEDICINE >> NEWS
Patient Workshop On Trigeminal Neuralgia Scheduled

LOS ANGELES (December 28, 1998) -- A free patient workshop for individuals who suffer from trigeminal neuralgia (severe facial pain) will be held Saturday, Jan. 23, 1999, at Cedars-Sinai Medical Center. The workshop will be held from 9 a.m.-12:30 p.m. in the Harvey Morse Auditorium, 8700 Beverly Blvd., Los Angeles. Trigeminal neuralgia, a disabling disorder of the fifth cranial (trigeminal) nerve, affects thousands of people worldwide and is universally considered to be the most painful affliction known to adult men and women. When a blood vessel comes in contact with this nerve, it creates pressure which can cause episodes of intense, stabbing, electric shock-like pain in the face. Historically, treatment options have been limited and only moderately effective, but recent advancements in skull base surgery have resulted in treatments that can eliminate pain immediately and permanently.

The Jan. 23 presentation is hosted by the Medical Center's Skull Base Institute and will include the latest in treatment options and symptom management, as well as a question-and-answer session. Led by Hrayr Shahinian, M.D., Director of the Skull Base Institute, the workshop will also include presentations by four other medical experts from Cedars-Sinai, UCLA Medical Center, and the San Diego Gamma Knife Center. Also participating in the workshop will be Terah Biszanta, West Coast Coordinator of the Trigeminal Neuralgia Association.

Victor Rosenfeld, M.D., an attending neurologist at Cedars-Sinai, will address medical management of this disorder. Robert Merrill, DDS, Clinical Director of the Oral-Facial Pain Clinic at UCLA Medical Center, will provide an overview of pain management options, and Kenneth Ott, M.D., neurosurgeon and medical director of the San Diego Gamma Knife Center will present information on the latest advances in Gamma Knife Radio-surgery.

Dr. Shahinian will provide information on Microvascular Decompression, a delicate surgical procedure in which s
'"/>

Contact: Sandra Van
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
28-Dec-1998


Page: 1 2

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patient with drug-resistant form of HIV identified
3. Patient knows best when it comes to ulcerative colitis, U-M study finds
4. Patients with cancer have highly increased risk for blood clots
5. Patients with previous heart attacks may not benefit from pacemaker implant
6. Patients with cancer detected on screening mammography undergo less toxic treatment
7. Patient protection laws dont favor health providers
8. Patients with moderate or severe hand dermatitis responsive to drug therapy
9. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
10. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
11. Patients undergoing weight loss surgery have high rates of H pylori bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Patient Workshop Trigeminal Neuralgia Scheduled

(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: